Print Email Facebook Twitter Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors Title Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors Author Verhaagh, S. de Jong, E. Goudsmit, J. Lecollinet, S. Gillissen, G. de Vries, M. van Leuven, K. Que, I. Ouwehand, K. Mintardjo, R. Weverling, G.J. Radošević, K. Richardson, J. Eloit, M. Lowik, C. Quax, P. Havenga, M. TNO Kwaliteit van Leven Publication year 2006 Abstract Wild-type strains of mice do not express CD46, a high-affinity receptor for human group B adenoviruses including type 35. Therefore, studies performed to date in mice using replication-incompetent Ad35 (rAd35) vaccine carriers may underestimate potency or result in altered vector distribution. Here, it is reported that CD46 transgenic mice (MYII-strain) express CD46 in all major organs and that it functions as a receptor for rAd35 vectors. Similar to monkeys and humans, MYII mice highly express CD46 in their lungs and kidneys and demonstrate low expression in muscle. Upon intravenous administration, rAd35 vector genomes as well as expression are detected in lungs of MYII mice, in contrast to wild-type littermates. Expression was predominantly detected in lung epithelial cells. Upon intramuscular administration, the initial level of luciferase expression is higher in MYII mice as compared with wild-type littermates, in spite of the fact that CD46 expression is low in muscle of MYII mice. The higher level of expression in muscle of MYII mice results in prolonged gene expression as assessed by CCD camera imaging for luciferase activity. Finally, a significant dose-sparing effect in MYII mice as compared with wild-type littermates on anti-SIVgag CD8+ T-cell induction following intramuscular vaccination with an rA35.SIVgag vaccine was observed. This dose-sparing effect was also observed when reinfusing dendritic cells derived from MYII mice after exposure to rAd35.SIVgag vaccine as compared with rAd35.SIVgag exposed dendritic cells from wild-type littermates. It was concluded that MYII mice represent an interesting preclinical model to evaluate potency and safety of rAd35 vectors. © 2006 SGM. Chemicals / CAS: Antigens, CD46 Subject BiologyBiomedical ResearchAdenovirus vectorBeta galactosidaseCD8 antigenGag proteinLuciferaseMembrane cofactor proteinSimian immunodeficiency virus vaccineAnimal cellAnimal experimentAntigen expressionAntigen functionCameraCD8+ T lymphocyteCellular immunityControlled studyDendritic cellDrug potencyDrug safetyFemaleGene expressionHuman adenovirusImaging systemKidney cellLung alveolus epitheliumMaleMouseMouse strainMuscle cellNonhumanReceptor affinityTransgenic mouseViral gene delivery systemVirus replicationWild typeAdenoviruses, HumanAnimalsAntigens, CD46Genetic VectorsHumansMiceMice, TransgenicVirus ReplicationAdenoviridaeAnimaliaHuman adenovirusMus musculusSimian immunodeficiency virus To reference this document use: http://resolver.tudelft.nl/uuid:af88071f-a1c4-4ef8-8050-3f1aff402b73 DOI https://doi.org/10.1099/vir.0.81293-0 TNO identifier 239103 ISSN 0022-1317 Source Journal of General Virology, 87 (2), 255-265 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.